---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-285259"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:53:29.580361+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks shifts to royalty-driven model, authorizes $125M buyback; appoints Platshon as CIO

## Summary
- Eligible for up to $440M in near-term milestones from Ziihera GEA approvals ($250M US, $100M EU, $75M Japan, $15M China).
- Board authorized $125M share repurchase program; prior $60M buyback retired ~4.4M shares (6% of outstanding).
- Cash and investments $299.4M as of Sep 30, 2025; with milestones expects to fund operations beyond 2028.
- Scott Platshon stepped down from board, appointed Acting CIO to manage healthcare asset aggregation strategy.
- Also eligible for up to $434M in additional milestones from J&J for pasritamig Phase 3 program.

## SEC filing metadata
- accession: 0001193125-25-285259
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312525285259/0001193125-25-285259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312525285259/d851143d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-285259
- JSON: https://secwatch.observer/filing/0001193125-25-285259.json
- Plain text: https://secwatch.observer/filing/0001193125-25-285259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.